Bulk Active Ingredients from Pfizer CentreSource - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pfizer CentreSource (PCS) has an established reputation for providing high quality Bulk Active Ingredients to the global fine chemicals marketplace. Our broad range of corticosteroids and hormonal steroids is used in a wide variety of sterile-manufacturing-packaging indications. Pfizer is a leading supplier of fine chemicals, steroid APIs, and steroid intermediates. Pfizer’s strength among steroid API suppliers is derived from our backward-integrated production platform based on soy sterol bioconversion and innovative chemical synthesis.

PCS corticosteroid offerings include dexamethasone, hydrocortisone, hydrocortisone acetate, prednisone, and spironolactone.

Hormonal Steroid products from PCS include: progesterone, megestrol acetate, testosterone, testosterone cypionate, and testosterone propionate.

PCS also supplies two grades of neomycin sulfate antibiotic, including Neomycin Sulfate Powder USP/EP and Neomycin Sulfate Micronized USP/EP.

For advanced intermediates, Pfizer’s unique GMP compliant process utilizes soybean-derived sterols and proprietary fermentation processes to create a very broad intermediate platform. This is done at a large scale, a far more efficient process than operations used by competing steroid manufacturers.

Pfizer CentreSource (PCS)
Website:  www.pfizercentresource.com
Email: Kenneth.F.Ball@pfizer.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
FindPharma Custom Search

Click here